<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00724477</url>
  </required_header>
  <id_info>
    <org_study_id>P05103</org_study_id>
    <nct_id>NCT00724477</nct_id>
  </id_info>
  <brief_title>Retrospective Evaluation of the Percentage of Subjects Who Have Reached Their LDL-C Objectives After Treatment With INEGY (Study P05103)(COMPLETED)</brief_title>
  <official_title>PRAGMATIC (This is the True Official Title of the Protocol for This Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study is to determine the percentage of patients who met the
      low-density lipoprotein cholesterol (LDL-C) objective with INEGY, that were not under statin
      monotherapy treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The type of patient sampling used was consecutive patient sampling
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Reaching the Targeted LDL-C Levels</measure>
    <time_frame>1 to 3 months after starting treatment</time_frame>
    <description>A subject was considered to have met targeted LDL-C levels (been controlled) if:
subject had no cardiovascular (CV) risk factors and level of LDL-C after initiating INEGY was lower than 2.2 g/L,
subject had only 1 CV risk factor and level of LDL-C after initiating INEGY was lower than 1.9 g/L,
subject had 2 CV risk factors and level of LDL-C after initiating INEGY was lower than 1.6 g/L,
subject had 3 or more CV risk factors and level of LDL-C after initiating INEGY was lower than 1.3 g/L,
subject had a high CV risk and level of LDL-C after initiating INEGY was lower than 1 g/L.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">1663</enrollment>
  <condition>Primary Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>Subjects treated with INEGY</arm_group_label>
    <description>Subjects suffering from primary hypercholesterolemia that are not controlled by statins as a monotherapy, and are treated with INEGY</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INEGY</intervention_name>
    <description>Ezetimibe 10mg - Simvastatine 20 mg or 40 mg; Tablet - OD; Patient currently treated for INEGY for at least 4 weeks</description>
    <arm_group_label>Subjects treated with INEGY</arm_group_label>
    <other_name>SCH 465981</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects suffering from primary hypercholesterolemia that are not controlled by statins as
        a monotherapy, and are treated with INEGY
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  man or woman aged over 18;

          -  patient suffering from primary hypercholesterolemia;

          -  patient justifying treatment with INEGY® (2nd intention);

          -  patient currently treated with INEGY® for at least 4 weeks;

          -  patient with a lipid profile before treatment with INEGY®, documenting a level of
             LDL-C exceeding the therapeutic objective under treatment with a statin as
             monotherapy;

          -  patient with an evaluation of lipid disorder (EAL) treated with INEGY®, performed
             within 1 to 3 months of starting treatment.

        Exclusion Criteria:

          -  patient not previously treated with a statin;

          -  patient previously treated with a combination of hypolipemics;

          -  patient treated with INEGY® as first intention;

          -  patient treated with INEGY® for less than 4 weeks;

          -  patient already included in this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>France</country>
  </removed_countries>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 25, 2008</study_first_submitted>
  <study_first_submitted_qc>July 25, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 29, 2008</study_first_posted>
  <results_first_submitted>November 24, 2009</results_first_submitted>
  <results_first_submitted_qc>February 3, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 26, 2010</results_first_posted>
  <last_update_submitted>September 28, 2015</last_update_submitted>
  <last_update_submitted_qc>September 28, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ezetimibe, Simvastatin Drug Combination</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Subjects Treated With INEGY</title>
          <description>Subjects suffering from primary hypercholesterolemia that were not adequately controlled by statins as a monotherapy, and were treated with INEGY. INEGY is composed of a combination of ezetimibe (10 mg) and simvastatin (20 or 40 mg). The dosage of the study treatment is one tablet per day ezetimibe/simvastatin (10 mg/20 mg or 10 mg/40 mg).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1663">This safety population (SAF)analysed consisted of all patients who took at least one tablet of INEGY</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1663"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Subjects Treated With INEGY</title>
          <description>Subjects suffering from primary hypercholesterolemia that were not adequately controlled by statins as a monotherapy, and were treated with INEGY. INEGY is composed of a combination of ezetimibe (10 mg) and simvastatin (20 or 40 mg). The dosage of the study treatment is one tablet per day ezetimibe/simvastatin (10 mg/20 mg or 10 mg/40 mg).</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1663"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.6" spread="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="585"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1078"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1663"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Reaching the Targeted LDL-C Levels</title>
        <description>A subject was considered to have met targeted LDL-C levels (been controlled) if:
subject had no cardiovascular (CV) risk factors and level of LDL-C after initiating INEGY was lower than 2.2 g/L,
subject had only 1 CV risk factor and level of LDL-C after initiating INEGY was lower than 1.9 g/L,
subject had 2 CV risk factors and level of LDL-C after initiating INEGY was lower than 1.6 g/L,
subject had 3 or more CV risk factors and level of LDL-C after initiating INEGY was lower than 1.3 g/L,
subject had a high CV risk and level of LDL-C after initiating INEGY was lower than 1 g/L.</description>
        <time_frame>1 to 3 months after starting treatment</time_frame>
        <population>This was the efficacy population per protocol (PP) targeted for study treatment, and consisted of patients having taken INEGY at least once, with a primary efficacy criterion available (presence of risk factors or not plus lipid assessment after introduction of INEGY), and showing no major deviations from the protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Subjects Treated With INEGY</title>
            <description>Subjects suffering from primary hypercholesterolemia that were not adequately controlled by statins as a monotherapy, and were treated with INEGY. INEGY is composed of a combination of ezetimibe (10 mg) and simvastatin (20 or 40 mg). The dosage of the study treatment is one tablet per day ezetimibe/simvastatin (10 mg/20 mg or 10 mg/40 mg).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reaching the Targeted LDL-C Levels</title>
          <description>A subject was considered to have met targeted LDL-C levels (been controlled) if:
subject had no cardiovascular (CV) risk factors and level of LDL-C after initiating INEGY was lower than 2.2 g/L,
subject had only 1 CV risk factor and level of LDL-C after initiating INEGY was lower than 1.9 g/L,
subject had 2 CV risk factors and level of LDL-C after initiating INEGY was lower than 1.6 g/L,
subject had 3 or more CV risk factors and level of LDL-C after initiating INEGY was lower than 1.3 g/L,
subject had a high CV risk and level of LDL-C after initiating INEGY was lower than 1 g/L.</description>
          <population>This was the efficacy population per protocol (PP) targeted for study treatment, and consisted of patients having taken INEGY at least once, with a primary efficacy criterion available (presence of risk factors or not plus lipid assessment after introduction of INEGY), and showing no major deviations from the protocol.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1354"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="740"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>4 weeks to 3 months</time_frame>
      <desc>Adverse events were recorded from the introduction of INEGY to the first assessment after introduction of INEGY</desc>
      <group_list>
        <group group_id="E1">
          <title>Subjects Treated With INEGY</title>
          <description>Subjects suffering from primary hypercholesterolemia that were not adequately controlled by statins as a monotherapy, and were treated with INEGY. INEGY is composed of a combination of ezetimibe (10 mg) and simvastatin (20 or 40 mg). The dosage of the study treatment is one tablet per day ezetimibe/simvastatin (10 mg/20 mg or 10 mg/40 mg).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (11.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1663"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1663"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1663"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1663"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The results of this non-interventional study can be published or presented by members of the scientific committee after revision and agreement by Schering-Plough, and in such a way that the confidential information and industrial property are not revealed. Before publication or presentation, a copy of the final text must be sent by the member(s) of the scientific committee to Schering-Plough for comment.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

